These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11763165)

  • 21. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Heat shock proteins: new target in cytoprotective and tumor therapy].
    Bao XQ; Liu GT
    Yao Xue Xue Bao; 2008 Mar; 43(3):234-40. PubMed ID: 18630257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.
    Okada M; Itoh H; Hatakeyama T; Tokumitsu H; Kobayashi R
    Biochem J; 2003 Sep; 374(Pt 2):433-41. PubMed ID: 12803546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsp90: the vulnerable chaperone.
    Chiosis G; Vilenchik M; Kim J; Solit D
    Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional specificity of co-chaperone interactions with Hsp90 client proteins.
    Riggs DL; Cox MB; Cheung-Flynn J; Prapapanich V; Carrigan PE; Smith DF
    Crit Rev Biochem Mol Biol; 2004; 39(5-6):279-95. PubMed ID: 15763706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hsp90 as a therapeutic target in patients with oesophageal carcinoma.
    Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J
    Expert Opin Ther Targets; 2010 Mar; 14(3):317-28. PubMed ID: 20148718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of HSP90 molecular chaperones: moving into the clinic.
    Garcia-Carbonero R; Carnero A; Paz-Ares L
    Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
    Saxena AK; Saxena S; Chaudhaery SS
    SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer.
    Chiosis G
    Expert Opin Ther Targets; 2006 Feb; 10(1):37-50. PubMed ID: 16441227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of radicicol analogues.
    Soga S; Shiotsu Y; Akinaga S; Sharma SV
    Curr Cancer Drug Targets; 2003 Oct; 3(5):359-69. PubMed ID: 14529387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
    Whitesell L; Lin NU
    Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and prospects for targeting Hsp90 to treat fungal infections.
    Veri A; Cowen LE
    Parasitology; 2014 Aug; 141(9):1127-37. PubMed ID: 24560124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens.
    Cowen LE
    Curr Opin Microbiol; 2013 Aug; 16(4):377-84. PubMed ID: 23588026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
    Reikvam H; Ersvaer E; Bruserud O
    Curr Cancer Drug Targets; 2009 Sep; 9(6):761-76. PubMed ID: 19754360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural product origins of Hsp90 inhibitors.
    Uehara Y
    Curr Cancer Drug Targets; 2003 Oct; 3(5):325-30. PubMed ID: 14529384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibiting HSP90 to treat cancer: a strategy in evolution.
    Whitesell L; Santagata S; Lin NU
    Curr Mol Med; 2012 Nov; 12(9):1108-24. PubMed ID: 22804235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design of Allosteric and Selective Inhibitors of the Molecular Chaperone TRAP1.
    Sanchez-Martin C; Moroni E; Ferraro M; Laquatra C; Cannino G; Masgras I; Negro A; Quadrelli P; Rasola A; Colombo G
    Cell Rep; 2020 Apr; 31(3):107531. PubMed ID: 32320652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.